InMode Ltd. (INMD) shares fell 8.82% as mixed guidance and regulatory concerns weigh on investor sentiment.

InMode Ltd. (INMD) shares fell 8.82% in pre-market trading on Jan. 9, 2026, marking one of the stock’s steepest declines in recent months. The sharp drop came amid renewed investor caution following mixed guidance from the medical aesthetics firm on its long-term growth trajectory.

Analysts suggest the selloff reflects concerns over regulatory headwinds in key markets and slowing adoption of the company’s newer non-invasive treatments. While InMode has historically benefited from the rising demand for cosmetic procedures, recent earnings reports highlighted margin pressures from price competition in its core markets.

Investors remain wary of macroeconomic risks, including tightening credit conditions that could curb discretionary spending on elective procedures. The stock’s volatility underscores broader challenges in the aesthetics sector as companies navigate shifting consumer priorities and evolving reimbursement policies in healthcare markets.

Experts are now watching whether the stock will find support as it approaches key levels previously identified in technical analysis. Meanwhile, the company’s guidance has raised questions about its ability to maintain profitability in a highly competitive landscape. Market participants are also assessing the potential for regulatory changes that could further impact the firm’s expansion plans.

Despite the recent drop, some long-term investors remain bullish, pointing to the continued growth in demand for non-surgical aesthetic treatments as a tailwind for the industry. However, near-term performance may remain fragile until the company can demonstrate stronger execution and clearer strategic direction.